Methylmalonic Acid (MMA) and Vitamin B12 Deficiency
What is MMA and Why Does It Matter?
Methylmalonic acid (MMA) is a functional biomarker that rises when your cells lack sufficient adenosylcobalamin (the mitochondrial form of vitamin B12). This active B12 form is a cofactor for the enzyme methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to succinyl-CoA. Without enough usable B12, methylmalonyl-CoA accumulates and is converted to MMA, which then spills into blood and urine.
For patients with PA, autoimmune gastritis, or other absorption issues, MMA often becomes elevated earlier and more specifically than serum B12 levels alone. It reflects intracellular/metabolic B12 deficiency—sometimes even when total serum B12 appears in the “normal” or low-normal range (the common grey zone of ~150–400 pg/mL or 110–300 pmol/L). Like other B12-related tests, MMA should be tested before treatment starts.
Key point: High MMA is one of the most specific indicators of functional B12 shortage at the tissue level.
Common Reasons for Elevated MMA (Beyond B12 Deficiency)
MMA is not 100% specific to B12 deficiency. Levels can also rise due to:
- Renal impairment (most frequent confounder — reduced clearance; eGFR matters a lot). In kidney disease, urine MMA testing may be more reliable than serum.
- Dehydration or hypovolemia
- Thyroid dysfunction
- Gut bacterial overgrowth (increased propionate production)
- Rare inherited methylmalonic acidurias
Recent antibiotics can sometimes produce falsely lower (or normalised) MMA by reducing propionate-producing gut flora. Best to test before starting B12 or antibiotics if possible.
Treatment response: B12 therapy typically lowers MMA quickly. Retesting after 1–2 months can help confirm that a deficiency was present, especially useful for borderline cases.
MMA vs. Other B12 Tests
MMA and homocysteine (tHcy) are generally more sensitive for detecting B12 deficiency than serum B12 alone, especially in the “grey zone” (serum B12 ~150–400 pg/mL or 110–300 pmol/L).
MMA is more specific to B12 deficiency than tHcy (which is also elevated in folate/B6 deficiency, renal issues, hypothyroidism, etc.).
Holotranscobalamin (holoTC) is another functional marker gaining use.
No gold standard test exists. Some people with PA symptoms have normal MMA, tHcy, and serum B12 yet respond well to B12 treatment. If you have neurological symptoms (neuropathy, ataxia, cognitive changes), myelopathy, or classic PA features, many specialists recommend not delaying treatment based on labs alone. Clinical response is often the ultimate “test.”
Reference Ranges, Grey Zones, and Interpretation
Lab “normal” ranges for serum/plasma MMA vary (commonly <0.27–0.45 µmol/L). Literature and symptom-focused clinicians sometimes use lower cutoffs (~0.21–0.318 µmol/L). Patients with values in the grey area and distinct B12 deficiency-related should be treated and, if improvement occurs, that treatment should be continued.
Age-specific interpretation is important. MMA is very low in infants, rises gradually, and can be higher in the elderly even without overt deficiency. Standard adult ranges may not fit children or older adults well. Reference ranges usually based on blood samples from healthy, adult individuals. However, values can differ between age groups, and healthy adults are not necessarily representative for all age groups. Functional B12 deficiency (normal serum B12 but elevated MMA) is increasingly recognized and linked to poorer outcomes in some studies.
If MMA is borderline and symptoms typical of PA/B12 deficiency are present, many experts support starting treatment and continuing treatment if there is clear improvement (hematologic, neurologic, or energy-related).
Bottom line: MMA is a valuable tool for detecting and confirming B12 deficiency, but no gold standard exists for B12 deficiency diagnosis. Over-reliance on any single test risks missing treatable cases with potentially severe consequences (hematologic, neurologic, cognitive). Early, adequate B12 replacement remains the priority.